ITE

Question 1

Tixagevimab/cilgavimab indicaiton

Answer 1

Not recommended for any cancer patients due to ineffectivness against COVID-19 variants

Question 2

SE to know with methadone

Answer 2

• QTc prolongation, contraindicated with QTc greater than 500

Question 3

Medications contraindicated with palbociclib

Answer 3

Strong CYP3A4 inhibitors

Question 4

If a patient is hospitalized for reason unrelated to study drug does it need be reported?

Answer 4

Yes, hospitalization is considered a serious adverse event and must be reported during clinical trials regardless of reason for admission

Question 5

NTRK inhibitors SE to know + when dose modification is recommended

Answer 5

• neurotoxicity – memory/cognitive impairment
• G3-4 neurological adverse events

Question 6

Klinefelter associated with increased risk of which tumors?

Answer 6

Germ cell tumors, particularly of mediastinum

Question 7

Clinical benefit of bevacizumab in ovarian cancer

Answer 7

OS benefit

Question 8

Malignancy associated with pure red cell aplasia

Answer 8

Thymoma

Question 9

Cause of anemia in patient with renal failure

Answer 9

Secondary hyperparathyroidism

Question 10

Management of triple positive APLS patient without thrombosis history

Answer 10

Aspirin

Question 11

Cause if idiopathic splanchnic venous thrombosis

Answer 11

JAK2 V617F mutation (in 30% of cases)

Question 12

Prophylaxis for women with inherited thrombophilias and recurrent early spontaneous abortion

Answer 12

NO role for anticoagulation

Question 13

Drug to avoid in active HIT

Answer 13

4 factor PCC (contains heparin)

Question 14

Primary predictor of CNS involvement at diagnosis in ALL

Answer 14

Extramedullary disease

Question 15

Prophylaxis for mucositis for patients on high-dose melphalan

Answer 15

Oral cryotherapy

Question 16

Motixafortide 1) use 2) mechanism

Answer 16

1) Stem cell mobilizer used in combination with GCSF
2) CXCR4 antagonist

Question 17

Clinical benefit of myeloablative conditioning for pts with MDS and AML undergoing transplant

Answer 17

Improved relapse-free survival

Question 18

Medication that needs to be held prior to plasma exchange and why

Answer 18

• ACE inhibitors
• Need to be stopped 24 hours before to avoid risk of anaphylaxis

Question 19

Impact of factor XIII deficiency on PT and aPTT

Answer 19

No effect

Question 20

How to reduce CMV transmission with PRBC transfusions

Answer 20

Leukoreduction

Question 21

Contraindication to high-dose methotrexate transfusion

Answer 21

Effusions

Question 22

Rasburicase mechanism

Answer 22

Recombinant urate oxidase

Question 23

Asciminib mechanism of action

Answer 23

Asciminib is described as a “STAMP inhibitor,” which means “specifically targeting the ABL myristoyl pocket.” The wild-type ABL has a myristoylated N-terminus, which binds to an allosteric site, but the ABL fusion protein does not have the myristoylated domain. In the wild-type protein, when myristoylated N-terminus binds to the allosteric site, the kinase has reduced activity. Since the mutant fusion protein does not have the myristoylated N-terminus domain, it is not subject to this form of regulation, and thus the fusion protein is constitutively active. Asciminib binds to the allosteric site, resulting in an inhibition of bcr-abl activity.[12]